search
All Posts By

Beth Newcomb

Fraud is rampant, but good hospice care exists. Here’s a guide to making the right choice (Los Angeles Times)

By In the News

Los Angeles Times quoted Susan Enguidanos in a column on hospice fraud. “The biggest complaint,” she said of consumer reviews of hospice organizations on Google and Yelp was that hospice staff didn’t show up as much as expected. “They said they would come,” Enguidanos said, paraphrasing a typical response, “and they just didn’t show up.” The column was widely republished, including in Yahoo, AOL, and MSN.

Website Helps Dementia Patients And Caregivers Bond, Reminisce (U.S. News & World Report)

By In the News

U.S. News & World Report (via HealthDay) featured a clinical trial led by Francesca Falzarano and collaborators at Weill Cornell Medicine evaluating how a web app could promote reminiscence therapy between dementia patients and their caregivers. “The idea is that getting them talking about those memories will promote the relationship between the person with dementia and the caregiver, which can improve numerous outcomes,” Falzarano said. News Medical, Cornell Chronicle, and others also featured the study.

Many peptides have names that sound like Yiddish words. Here’s why. (Jewish Telegraphic Agency)

By In the News

Jewish Telegraphic Agency featured Pinchas Cohen, his research discovering mitochondrial peptides, and how his team gave many of them Yiddish-sounding names. The article noted Cohen’s Jewish and Israeli heritage and mentioned the microproteins SHLP (pronounced “schlep”), SHMOOSE, and MENTSH, as well as unpublished peptides NOSH and PUTZ. Each is a legitimate scientific acronym, carefully reverse-engineered to land on a Yiddish word. “I always give the students and postdocs the chance to name the project they’re working on,” Cohen said. “But I get veto power. They’ve already learned that the best way to get me to say yes is to come up with something really cute.”

Cohen also discussed the therapeutic potential of mitochondrial microproteins and the need for further research, especially as peptides gain popularity as off-label supplements. “These are potent biological molecules,” he said. “They should be used under the supervision of a physician, and when they’re being produced in reliable manufacturing facilities — most of which is not happening right now.” The article also appeared in the Times of Israel, Forward, Jewish Post & News (Canada), Cleveland Jewish News, Pittsburgh Jewish Chronicle and others.